Digestibility of Selected Resistant Starches in Humans

NCT01939600 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-11-18

No results posted yet for this study

Summary

Dietary fiber is a type of carbohydrate which is not digested in the human small intestine. Whole grains are a source of dietary fiber that are used to promote health; however, using whole grains in commercial products results in a different taste and/or texture than the usual products made from refined grains. Thus, other types of high-fiber ingredients have been developed which can be incorporated into food products with less effect on their taste and/or texture. An example of this is resistant starch, defined as starch which is not digested in the human small intestine. The digestibility of starch is usually determined in-vitro; however, there is evidence that such methods may overestimate the amount of resistant starch by as much as 100%. The measurement of the amount of carbohydrate in the ileal effluent, digestive waste, of subjects with an ileostomy is considered to be the best in-vivo method of starch digestibility. The subjects collect ileal effluent during the day during which time they consume a polysaccharide-free diet. There is evidence that resistant starch consumed at breakfast is completely recovered in ileal effluent 8-10hr after consumption. The purpose of this study will be to compare the carbohydrate content recovered in ileal effluent of 10 subjects with a conventional ileostomy.

Conditions

  • Malabsorption; Carbohydrate
  • Ileostomy - Stoma

Interventions

OTHER

Starch-free breakfast

Starch-free breakfast alone

OTHER

Hi-Maize 260

Starch-free breakfast plus 55.3g Hi-Maize 260

OTHER

Hylon VII

Starch-free breakfast plus 56.9g Hylon VII

OTHER

Amioca

Starch-free breakfast plus 56.4g amioca starch

Sponsors & Collaborators

  • Ingredion Incorporated

    collaborator INDUSTRY
  • University of Toronto

    collaborator OTHER
  • Glycemic Index Laboratories, Inc

    collaborator INDUSTRY
  • Iowa State University

    collaborator OTHER
  • Unity Health Toronto

    lead OTHER

Principal Investigators

  • Thomas M. Wolever, MD, PhD · Unity Health Toronto

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2013-12-31
Completion
2014-08-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01939600 on ClinicalTrials.gov